Stephen Hanauer News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Johnson & Johnson has settled its lawsuit with Amgen regarding the latter company’s Stelara biosimilar, clearing the way for a January 2025 release date in the United States, according to results of a federal court filing. Meanwhile, the rheumatology world awaits the debut of other ustekinumab biosimilars in the market — and what they may portend for patient care moving forward

I have long wondered how the nuclear industry measures and manages risk. I am familiar with risk management systems used by process safety engineers, insurance companies, the airline industry, data/software engineers, etc. Each one employs some sort of risk matrix and performs qualitative and/or quantitative risk analysis by identifying sets of scenarios, their possible costs

A new history reveals that federal regulators consistently assured Americans that the risks of a massive accident were “vanishingly small”—even when they knew they had insufficient evidence to prove it.

Meta-analysis ranks infliximab and others, but experts urge results are not ready for prime time

After the first year postdiagnosis, patients with celiac disease had an almost 4-fold higher risk of IBD, and patients with IBD had more than a 5-fold higher risk of celiac disease.